• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

How Accurate are At-Home Screening Tests for High-Risk HPV and STDs?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Des Marais et al. (Obstetrics & Gynecology, 2018) assessed the validity and acceptability of at-home self-collection kit to test for human papillomavirus (HPV) and STDs in women at higher risk as a result of underscreening for cervical cancer

METHODS:

  • Observational study
    • 2nd phase of My Body, My Test study
  • Participants
    • 30–64 years of age | No history of Pap testing in the past 4 years | Household income below 250% of the poverty level | Not pregnant | No previous hysterectomy | Uninsured, underinsured, or on Medicaid
  • Participants provided cervicovaginal samples by one of 3 routes
    • Self-home (sample returned by mail)
    • Self-clinic (sample handed to nurse at visit)
    • Clinician
  • Samples were tested for
    • High-risk HPV (14 high-risk HPV genotypes, with positive results reflexed for types 16 and for 18/45)
    • Chlamydia trachomatis
    • Neisseria gonorrhoeae
    • Trichomonas vaginalis
    • Mycoplasma genitalium
  • Cervical samples were also tested by liquid-based cytology
  • Primary outcome: Clinical performance of high-risk HPV testing on self-collected cervicovaginal samples vs clinician-collected samples for ≥CIN2
  • Other outcomes
    • Chlamydia trachomatis | Neisseria gonorrhoeae | Trichomonas vaginalis | Mycoplasma genitalium

RESULTS:

  • 193 women had conclusive high-risk HPV results for all three samples and cytology results
    • Median age: 45 years
    • Median time from last Pap: 5 years
  • Prevalence of high-risk HPV was similar between different screens
    • Self-home: 12.4%
    • Clinician: 11.4% (P=.79)
    • Self-clinic:15.5% (P=.21)
  • Positivity for high-risk HPV in all sample types increased with increasing grades of cervical abnormality (P<.001)
  • Self-home samples detected high-risk HPV in all
    • High-grade squamous intraepithelial lesions (HSIL)
    • CIN ≥2
  • Detection was comparable across sample types for
    • T vaginalis (range 10.2–10.8%)
    • M genitalium (3.3–5.5%)
    • C trachomatis (1.1–2.1%)
    • N gonorrhoeae (0–0.5%)
  • Acceptability
    • Most participants reported no difficulty understanding self-collection instructions (93.6%) and were willing to use self-collection in the future (96.3%)

CONCLUSION:

  • Self-home collection for HPV and STD screening was demonstrated to be a valid alternative among infrequently screened women
  • The authors state

“…future implementation research is needed on program efficacy and cost-effectiveness, including a comprehensive assessment of continuity from screening to treatment”

Learn More – Primary Sources:

Home Self-Collection by Mail to Test for Human Papillomavirus and Sexually Transmitted Infection

image_pdfFavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Guidance Update: Professional Organizations Align on Cervical Cancer Screening
Cervical Cytology and HPV Screening in the HIV Positive Woman
Cervical Cancer Screening Guidelines: The Role of Pap and HPV

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site